Analysts and Abivax's CEO believe the upcoming maintenance trial for its drug Obafazimod has a very high probability of success. This confidence is based on the historical rarity of drugs succeeding in the initial 'induction' phase but then failing in the longer 'maintenance' phase for ulcerative colitis.

Crohn's disease is a higher bar for drug approval than ulcerative colitis, often due to fibrotic strictures. Abivax has presented preclinical data suggesting its drug has anti-fibrotic properties. This is a key differentiator, as therapies that fail in Crohn's often lack this effect, providing a mechanistic rationale for potential success.

Abivax's drug has a novel, not fully understood mechanism (miR-124). However, analysts believe strong clinical data across thousands of patients can trump this ambiguity for doctors and regulators, citing historical precedents like Revlimid for drugs that gained approval despite unclear biological pathways.

Dr. Carbone argues that traditional metrics like median survival or response rate are less relevant for immunotherapies. The true measure of success is the percentage of patients alive at five or six years—the "tail of the curve"—as this indicates a durable, potentially curative, response.

While the FDA avoids providing an explicit number, analysis of previously approved drugs in this indication reveals a clear benchmark. A complete response (CR) rate of "about two-thirds" in the pivotal trial is the unofficial target companies like enGene must hit to be considered in the approvable range.

Analysts largely overlooked Abivax before its major data success because it was a European company with a recent US listing, its drug was repurposed from an initial indication in HIV, and investor attention in the IBD space was focused on other high-profile mechanisms like TL1A and S1Ps.

Protagonist believes its oral IL-23 blocker will not just compete with existing injectables but will capture a new market. They target the over 50% of eligible patients who currently take no therapy due to a dislike of injections or the safety profiles of other oral options, thereby expanding the total addressable market.

Despite many approved drugs for Inflammatory Bowel Disease (IBD), single-mechanism therapies consistently fail to get more than 30% of patients into remission. This recognized "therapeutic ceiling" exists because IBD is a multi-faceted disease. The next breakthrough requires attacking multiple biological pathways simultaneously with combination drugs to achieve significantly higher efficacy.

The placebo effect in gastrointestinal treatments is remarkably high, around 35-40%. This makes subjective patient feedback unreliable for assessing a therapy's true effectiveness and underscores the urgent need for objective, data-driven measurement tools.